When the Vermont Legislature took testimony for and against the legalization of marijuana in 2020, the group most opposed was the Vermont Medical Association. No surprise. The VMA stressed the health consequences of high potency pot and argued the public’s health would be threatened. It was a battle between the public’s health and the promise of millions in needed revenue for the state.
The big bucks argument prevailed. In 2024, the state received $8.1 million in sales taxes and $19.7 million in excise taxes. Clearly, the $28 million was not as much as supporters predicted, but it’s enough to protect it from any effort to rethink the wisdom behind legalization. The attention currently paid to the industry is about how it’s pursuing new and more powerful products and how to drive revenue. It’s a business. That’s what they do.
But it’s worth pausing to ask whether the state’s medical community was right to warn about its use and about the likelihood that, as the industry increased in size, the public’s health problems would increase along with it.
If you regard cardiologists as credible authorities on issues dealing with the heart, the answer is yes. This year, the Journal of the American College of Cardiology reviewed more than 4.6 million records to find that pot users were six times more likely to have a heart attack than non-users, and had correspondingly high risks for stroke and heart failure.
A “Business Insider” publication reported on a large meta-analysis in the HEART publication reporting that cannabis users had a 29 percent higher risk of heart attack and a 20 percent higher risk of stroke than non-users.
The reason is, obviously, the expanded use of cannabis products. But it’s also the dramatic increase in the products’ potency. When smoking pot became fashionable in the sixties, the average THC levels were around 1-3 percent. Today, the “average flower” has a THC level of between 17 percent and 28 percent, with the more potent strains being in the 30 percent to 40 percent range. Concentrates reach 50 percent to 100 percent. The goal of the cannabis providers is to give the customer a high that is higher and lasts longer, which also induces the customers to buy more.
Pretty basic.
Not only was the VMA clear in its opposition for public health reasons, it also warned about the link between high-THC use and psychosis, depression, and other mental health issues.
The response from the advocates remains unchanged. People will continue to use it; it’s best to have it be legal than not. The abuse of alcohol is more damaging. It’s hypocritical to go after cannabis use and not the use of alcohol. And, of course, there is the money for cash-starved Vermont.
We’ve always considered the alcohol-related argument ridiculous. The prevalence of one substance doesn’t mean all substances merit the same treatment, regardless of impact. But what can we do to lessen the negative impact of high THC products, acknowledging that the industry is still with us and won’t be dismantled?
The obvious approach is to limit the THC levels, something the Netherlands considered doing. That would be something the cannabis industry would strongly oppose, claiming it would cut into their profits and the state’s revenue.
But with the increased evidence that high THC cannabis use contributes measurably to the nation’s crisis with heart-related disease, why wouldn’t we consider it? If we can lobby against the use of tobacco, for health-related reasons, why can’t we lobby against high THC cannabis?
Or does money trump our health?
By Emerson Lynn
Comments
No comments on this item Please log in to comment by clicking here